San Francisco, CA, United States of America

Frederick Cohen

This inventor holds 29 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Genentech, Inc., Nurix Therapeutics, Inc., Achaogen, Inc.. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frederick Cohen. Retrieved from https://idiyas.com/inventor/frederick-cohen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 13)

% Patents Active = 65.5

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 14)

Average Co-Inventor Count = 5.8

ph-index = 7

Forward Citations = 248(Granted Patents)

Company Filing History:

Nurix Therapeutics, Inc.

Gilead Sciences, Inc.

patents

6. 1 out of 37

Inotek Pharmaceuticals Corporation

patents

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

CBL-B Inhibition

IAP Inhibitors

Antibacterial Agents

Piperidine Compounds

Triazole Compounds

Pyrimidine Compounds

Heterobicyclic Compounds

Bifunctional Degraders

Fibroblast Activation Protein

Azabicyclo-Octane

Dipyridylamines

Indenoisoquinolinone

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12653809 - UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION (2026-06-16),

2. 12485144 - 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF (2025-12-02),

3. 12234230 - Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof (2025-02-25),

4. 12091426 - Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof (2024-09-17),

5. 12049471 - Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof (2024-07-30),

6. 11963994 - Inhibitors of IAP (2024-04-23),

7. 11951133 - 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof (2024-04-09),

8. 11530229 - Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof (2022-12-20),

9. 11464802 - 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof (2022-10-11),

10. 11401267 - Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof (2022-08-02),

11. 11096982 - Inhibitors of IAP (2021-08-24),

12. 9868720 - C-linked heterocycloaklyl substituted pyrimidines and their uses (2018-01-16),

13. 9701622 - Antibacterial agents (2017-07-11),

14. 9586991 - Inhibitors of IAP (2017-03-07),

15. 9403758 - Antibacterial agents (2016-08-02),

Title: The Innovative Mind of Frederick Cohen

Introduction: Frederick Cohen, a visionary inventor based in San Francisco, CA, has made significant contributions to the world of technology through his groundbreaking inventions and patents.

Latest Patents: Frederick Cohen's latest patents include a cutting-edge cybersecurity software that revolutionizes data protection in the digital age, and a unique artificial intelligence algorithm designed to enhance user experience in online platforms.

Career Highlights: With a career spanning over two decades, Frederick Cohen has established himself as a leading figure in the tech industry. His innovative solutions have garnered international recognition and have been instrumental in shaping the future of cybersecurity and artificial intelligence.

Collaborations: Throughout his career, Frederick Cohen has collaborated with top tech companies, leading research institutions, and renowned universities to further advance his inventions. His collaborative spirit has led to the development of groundbreaking technologies that have transformed the way we interact with digital systems.

Conclusion: Frederick Cohen's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors. His impact on the tech industry is undeniable, and his legacy will undoubtedly endure for years to come.

Profile summary based on public USPTO records.